Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.
about
Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewOnset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agentsAdverse events in IBD: to stop or continue immune suppressant and biologic treatmentRosacea, Use of Tetracycline, and Risk of Incident Inflammatory Bowel Disease in WomenThe skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis.Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.The safety of vedolizumab for ulcerative colitis and Crohn's disease.Herpes Simplex Virus Sepsis in a Young Woman with Crohn's Disease.Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.Management of cutaneous disorders related to inflammatory bowel disease.The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies.Associated comorbidities in psoriasis and inflammatory bowel disease.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.
P2860
Q22241795-F5560DAF-3B5A-4746-B6FA-47A20A925A01Q22305935-7328A1EE-54EF-44E8-A1F9-55FD9AC4A671Q34073191-252264E5-F641-4751-B297-44E65FEB5804Q36479945-EACD493B-E01E-48CD-89E7-8A74E8E5338FQ37196596-4E2B7F47-4A9B-41CD-81F4-8DED225D690CQ38050938-8830B2E5-3F1D-4125-9154-0444AA2B4449Q38939797-55A155CA-9030-40BD-B3CA-9E3B4229F2C1Q39030608-B5E8105B-8FCD-4C79-9A2A-61133590968AQ39361308-2BF4503F-91A1-4946-8AC8-C7759A9CAD1FQ39869647-99AAB7CB-12C6-4918-BDB9-B7212CD4CDF1Q39985219-4E700D0C-BF03-48CC-AF33-7B9E9FC7DACFQ40140176-1E520020-6ACF-4DD5-B6F4-D086CA3CED81Q41807889-DEA8054C-FE6D-488C-8C24-6119A41BF2A7Q42406766-7DC1EA7C-380A-4574-B3D8-ECD9F8AD52ABQ44803722-22B55D93-3892-4247-9885-53D9A44A072BQ45907246-300C3706-2248-4D78-9664-80A1EF844E43Q47805665-CD3D6839-8FDF-4970-B9F5-B1D804B3F6B4Q50681708-1845E62D-17B5-49F4-B857-4093F3C7D0AB
P2860
Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Frequency, phenotype, outcome, ...... matory bowel disease patients.
@ast
Frequency, phenotype, outcome, ...... matory bowel disease patients.
@en
type
label
Frequency, phenotype, outcome, ...... matory bowel disease patients.
@ast
Frequency, phenotype, outcome, ...... matory bowel disease patients.
@en
prefLabel
Frequency, phenotype, outcome, ...... matory bowel disease patients.
@ast
Frequency, phenotype, outcome, ...... matory bowel disease patients.
@en
P2093
P2860
P356
P1476
Frequency, phenotype, outcome, ...... matory bowel disease patients.
@en
P2093
Andrea Steingräber
Daniel C Baumgart
Marina Azzaro
Sandra Philipp
P2860
P304
P356
10.1002/IBD.21643
P577
2011-02-23T00:00:00Z